CD8A and neoplasm: If certain types of immune cells in tumor tissues, such as intraepithelial CD3+CD8+CD45RO+ cells or stromal M1-like macrophages, could be used to predict the efficacy of certain immunotherapies, they may be attractive as an innovative biomarker using colonoscopy biopsies or surgically resected tissues prior to treatment.